Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125456941 | 12545694 | 1 | I | 20160701 | 20160711 | 20160711 | EXP | US-PFIZER INC-2016328586 | PFIZER | MEHTA, JAIDEEP. THORACIC EPIDURAL ANALGESIA TO CONTROL MALIGNANT PAIN UNTIL VIABILITY IN A PREGNANT PATIENT. JOURNAL OF PAIN RESEARCH. 2016;9:357-360 | 0.00 | Y | 0.00000 | 20160711 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125456941 | 12545694 | 1 | PS | FENTANYL CITRATE. | FENTANYL CITRATE | 1 | Transplacental | 10 ML(0.1% ROPIVACAINE WITH 2 ?G/ML FENTANYL),STARTED AT 10 ML/HR | U | 19115 | |||||||||
| 125456941 | 12545694 | 2 | SS | FENTANYL CITRATE. | FENTANYL CITRATE | 1 | Transplacental | 5 ML EVERY 20 MINUTES(0.1% ROPIVACAINE WITH 2 ?G/ML FENTANYL) WITH MAXIMUM OF 20 ML/HR | U | 19115 | |||||||||
| 125456941 | 12545694 | 3 | SS | FENTANYL CITRATE. | FENTANYL CITRATE | 1 | Transplacental | 8 ML/HR (0.1% ROPIVACAINE WITH 2 ?G/ML FENTANYL) | U | 19115 | |||||||||
| 125456941 | 12545694 | 4 | SS | ROPIVACAINE HYDROCHLORIDE. | ROPIVACAINE HYDROCHLORIDE | 1 | Transplacental | 10 ML(0.1% ROPIVACAINE WITH 2 ?G/ML FENTANYL), STARTED AT 10 ML/HR | U | 90194 | 10 | ML | SOLUTION FOR INJECTION | ||||||
| 125456941 | 12545694 | 5 | SS | ROPIVACAINE HYDROCHLORIDE. | ROPIVACAINE HYDROCHLORIDE | 1 | Transplacental | 5 ML EVERY 20 MINUTES(0.1% ROPIVACAINE WITH 2 ?G/ML FENTANYL) WITH MAXIMUM OF 20 ML/HR | U | 90194 | 5 | ML | SOLUTION FOR INJECTION | ||||||
| 125456941 | 12545694 | 6 | SS | ROPIVACAINE HYDROCHLORIDE. | ROPIVACAINE HYDROCHLORIDE | 1 | Transplacental | 8 ML/HR (0.1% ROPIVACAINE WITH 2 ?G/ML FENTANYL) | U | 90194 | SOLUTION FOR INJECTION | ||||||||
| 125456941 | 12545694 | 7 | SS | FENTANYL CITRATE. | FENTANYL CITRATE | 1 | Transplacental | 12.5 MG/HR PATCHES | U | 0 | |||||||||
| 125456941 | 12545694 | 8 | SS | OXYCODONE | OXYCODONE | 1 | Transplacental | 5-10 MG, AS NEEDED EVERY 4 HOURS | U | 0 | |||||||||
| 125456941 | 12545694 | 9 | SS | OXYCODONE | OXYCODONE | 1 | Transplacental | 10 MG, 3X/DAY | U | 0 | 10 | MG | TID | ||||||
| 125456941 | 12545694 | 10 | SS | ACETAMINOPHENHYDROCODONE BITARTRATE | ACETAMINOPHENHYDROCODONE BITARTRATE | 1 | Transplacental | 10 MG/325 MG, EVERY 4-6 HOURS | U | 0 | TABLET | ||||||||
| 125456941 | 12545694 | 11 | SS | ACETAMINOPHENHYDROCODONE BITARTRATE | ACETAMINOPHENHYDROCODONE BITARTRATE | 1 | Transplacental | 10 MG/325 MG, EVERY 4 HOURS (ONE TO TWO TABLETS) | U | 0 | TABLET | ||||||||
| 125456941 | 12545694 | 12 | C | BUPIVACAINE. | BUPIVACAINE | 1 | Transplacental | 1 ML OF 0.25% | 0 | 1 | ML |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125456941 | 12545694 | 1 | Breakthrough pain |
| 125456941 | 12545694 | 4 | Breakthrough pain |
| 125456941 | 12545694 | 7 | Breakthrough pain |
| 125456941 | 12545694 | 8 | Breakthrough pain |
| 125456941 | 12545694 | 10 | Breakthrough pain |
| 125456941 | 12545694 | 12 | Epidural anaesthesia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125456941 | 12545694 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125456941 | 12545694 | Exposure during pregnancy | |
| 125456941 | 12545694 | Premature baby |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |